ClinicalTrials.gg
CompletedNCT03476655Updated Feb 3, 2025

Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India

An observational study in Leukemia, Lymphocytic, Chronic, B-Cell and Lymphoma, Mantle-Cell, sponsored by Johnson & Johnson Private Limited. Completed at 8 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Johnson & Johnson Private Limited (part of Johnson & Johnson) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson — 3 open to participants now, 7 under way, 2 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Johnson & Johnson.

Started
2018
with 2 others
Observational
7 of 26
2 open now
Registered
15th of 26
by date

Among the 26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson, this one is one of 3 that started in 2018, is one of 7 observational ones, and was the 15th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to describe the effectiveness (overall response rate [ORR] and time to progression [TPP]) of Ibrutinib therapy in participants with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

03

Conditions studied

  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Mantle-Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population include chronic lymphocytic leukemia (CLL) or mantle-cell lymphoma (MCL) participants treated with ibrutinib per routine clinical care before 30 April 2018 in India and who have progressed on at least one prior line of therapy or CLL participants with deletion 17p (deletions in the short arm of chromosome 17).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
  • CLL or MCL participants being newly initiated on Imbruvica treatment (ibrutinib capsule 140 mg) based on independent clinical judgment of treating physicians

Exclusion criteria

Exclusion Criteria:

  • Any to ibrutinib use according to the current version of the Prescribing information in India
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
40 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants with Chronic Lymphocytic Leukemia (CLL)

    This study will collect retrospective data on effectiveness and outcome parameters for participants of CLL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.

    Drug: Ibrutinib

  • Participants with Mantle Cell Lymphoma (MCL)

    This study will collect retrospective data on effectiveness and outcome parameters for participants of MCL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.

    Drug: Ibrutinib

Interventions

  • No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.

    Also known as: IMBRUVICA

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as achievement of complete response (CR) or partial response (PR) per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 guidelines for Chronic Lymphocytic Leukemia (CLL) and Mantle-cell Lymphoma (MCL). CR is defined as resolution of enlarged lymph nodes, spleen and liver; normalization of blood counts (neutrophils, hemoglobin, platelets); no residual CLL/MCL detectable in the bone marrow. PR is defined as 50 percent (%) or more reduction in size of enlarged lymph nodes, liver or spleen; 50% or more improvement of blood counts; 50% or more reduction in the blood lymphocyte count.

    Time frame: Up to 14 months

  2. Time to Progression (TTP)

    Time to progression will be reported for the observed participants receiving ibrutinib. TTP is defined as the period from study entry until objective disease progression (time from the date of randomization until disease progression or death due to progression, whichever occur first).

    Time frame: Up to 14 months

  3. Percentage of Participants with Complete Response (CR)

    Percentage of participants with CR will be reported. CR is defined as resolution of enlarged lymph nodes, spleen and liver; normalization of blood counts (neutrophils, hemoglobin, platelets); no residual CLL/MCL detectable in the bone marrow.

    Time frame: Up to 14 months

  4. Percentage of Participants with Partial Response (PR)

    Percentage of participants with PR will be reported. PR is defined as 50 percent (%) or more reduction in size of enlarged lymph nodes, liver or spleen; 50% or more improvement of blood counts; 50% or more reduction in the blood lymphocyte count.

    Time frame: Up to 14 months

  5. Percentage of Participants with Stable Disease (SD)

    Percentage of participants with SD will be reported. Participants who have not achieved a CR or a PR, and who have not exhibited progressive disease will be considered to have stable disease.

    Time frame: Up to 14 months

  6. Percentage of Participants with Progressive Disease (PD)

    Percentage of participants with PD will be reported. PD is defined as 50% or more increase in lymph nodes or the appearance of new enlarged lymph nodes; 50% or more increase in the size of the spleen or liver; 50% or more increase in blood lymphocyte count.

    Time frame: Up to 14 months

Secondary outcomes

  1. Median time to Response with Ibrutinib

    Median time to response with ibrutinib in CLL and MCL participants will be reported. Time to response is defined as the time from start of ibrutinib therapy until objective response (CR or PR assessed by the investigator, based on physical examinations, CT scans, laboratory results, and bone marrow examinations, according to the modified 2008 IWCLL response criteria).

    Time frame: Up to 14 months

  2. Change from Baseline in Hemoglobin Levels

    Change from baseline in blood hemoglobin level will be reported.

    Time frame: Baseline up to 14 months

  3. Change from Baseline in Platelet Counts

    Change from baseline in blood platelet counts will be reported.

    Time frame: Baseline up to 14 months

  4. Number of Participants with Response to Ibrutinib by Prior Lines of Therapy

    Number of participants, who progresses on at least one prior line of therapy, with response to ibrutinib will be reported.

    Time frame: Up to 14 months

  5. Number of Participants with Hematological and Non-hematological Adverse Drug Reactions (ADR)

    Number of participants with hematological and non-hematological ADR will be reported. An adverse drug reaction (ADR) is defined as a response to a medicinal (investigational or non-investigational) product that is noxious and unintended. The phrase "response to a medicinal product" means that a causal relationship between a medicinal product and an adverse event is possible, probable or very likely.

    Time frame: Up to 14 months

07

Study locations

8 sites
  • Apollo Hospitals International Limited
    Ahmedabad, 382428, India
  • Healthcare Global (HCG) Hospital
    Bangalore, 560013, India
  • Fortis Memorial Research Institute
    Gurgaon, 122002, India
  • Basavatarakam Indo-American Hospital
    Hyderabad, 500034, India
  • Bhagwan Mahaveer Hospital & Research Centre
    Jaipur, 302017, India
  • Tata Medical Center
    Kolkata, 700156, India
  • All India Institute of Medical Sciences
    New Delhi, 110029, India
  • Yashoda Hematology Clinic
    Pune, 411002, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in May 2019, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2018
First posted
Mar 26, 2018
StartActual
Apr 28, 2018
Primary completionActual
May 14, 2019
CompletionActual
May 31, 2019
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03476655
Responsible party
Sponsor
First posted
Mar 26, 2018
Start date
Apr 28, 2018
Primary completion
May 14, 2019
Completion
May 31, 2019
Last update
Feb 3, 2025

Study contacts

Johnson & Johnson Private Limited Clinical Trial
study director · Johnson & Johnson Private Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion